InvestorsHub Logo
Followers 13
Posts 2213
Boards Moderated 0
Alias Born 08/11/2017

Re: None

Thursday, 10/22/2020 9:02:00 AM

Thursday, October 22, 2020 9:02:00 AM

Post# of 1716
Cardiff Oncology initiated with a Buy at H.C. Wainwright

Cardiff Oncology initiated with a Buy at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Cardiff Oncology with a Buy rating and $27 price target. The company's lead clinical-stage candidate, onvansertib, is a potent, highly selective, third-generation inhibitor of Polo-like kinase 1, Selvaraju tells investors in a research note. The analyst believes onvansertib could constitute a "best-in-class" Plk1 inhibitor.

https://thefly.com/n.php?id=3179540

MegaDeath, changed due to circumstances of COVID-19 pandemic.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRDF News